U.S. Sens. Dianne Feinstein (D-Calif.) and Susan Collins (R-Maine) introduced the Personal Care Products Safety Act (S. 1014) on April 20, 2015. The bill addresses a range of issues, including registration of facilities and products, mandatory recall authority, adverse and serious adverse event reporting, good manufacturing practices, and user fees. The legislation appears to have been drawn from Food, Drug, and Cosmetic Act (FDCA) provisions applicable to non-prescription drugs. The proposed requirements for adverse reporting would exceed those applicable to non-prescription drugs by requiring companies to report “serious” adverse events within 15 business days and all non-serious adverse events in an annual report. The U.S. Food and Drug Administra- tion’s (FDA’s) mandatory recall authority would be limited to instances in which the use or exposure to a cosmetic were likely to cause serious adverse health consequences or death, and the company refused to voluntarily recall the product. Additionally, FDA would be tasked with investigating at least five different cosmetic ingredients for safety each year. Implementation of these amendments to FDCA has been estimated to cost $20.6 million annually and would be covered by registration fees.